Shearman & Sterling advised the underwriters of Galera Therapeutics, Inc.’s initial public offering of 5 million shares of common stock at a public offering price of $12.00 per share, resulting in gross proceeds of approximately $60 million.  The shares began trading on the Nasdaq Global Market under the ticker symbol “GRTX” on November 7, 2019.  

BofA Securities, Citigroup and Credit Suisse acted as joint book-running managers for the offering and BTIG acted as co-manager.  

Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

The Team